Neal JT et al. indicate that the patient-derived tumor organoids using the air-liquid interface (ALI) technology can reserve the intrinsic tumor T-cell receptor profile and anti-PD-1/PD-L1-dependent human tumor-infiltrating lymphocyte (TIL) activation [114]. This evidence concerns the gene CD274 and neoplasm.